Clinical Report: Assessment of Androgen Receptor Expression in Endometrial Carcinoma
Overview
This study evaluates androgen receptor (AR) expression in endometrial carcinoma (EC) tissue samples and its correlation with clinicopathological parameters.
Background
Endometrial carcinoma is the most commonly diagnosed gynecological malignancy in developed countries, with rising incidence linked to obesity and metabolic dysfunction. Understanding the role of androgen signaling in EC is crucial.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
AR expression was evaluated in a cohort of 40 endometrial carcinoma tissue specimens.
AR may have tumor-suppressive activity in the endometrium, particularly in postmenopausal women.
Increased endogenous testosterone levels are associated with the risk of developing endometrioid and non-endometrioid tumors.
AR signaling may oppose estrogen-driven pro-proliferative networks in hormone-responsive tissues.
The study correlates AR expression with tumor differentiation, FIGO stage, and tumor grade.
Clinical Implications
The assessment of AR expression in endometrial carcinoma may provide insights into tumor behavior.
Conclusion
The study evaluates AR expression in endometrial carcinoma and its correlation with clinicopathological parameters.
